|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
Timothy J. Miller
|
|
gptkbp:clinicalTrialPhase
|
FBX-101 for Krabbe disease
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:facilityId
|
GMP manufacturing facility
|
|
gptkbp:facilitySize
|
175,000 square feet
|
|
gptkbp:focusesOn
|
rare genetic diseases
|
|
gptkbp:foundedYear
|
2020
|
|
gptkbp:founder
|
gptkb:Jane_Allen
Christopher D. Roche
Timothy J. Miller
|
|
gptkbp:headquartersLocation
|
gptkb:Grove_City,_Ohio,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Forge Biologics
|
|
gptkbp:industry
|
gptkb:biotechnology
gene therapy
|
|
gptkbp:investor
|
gptkb:Aisling_Capital
gptkb:Perceptive_Advisors
gptkb:RA_Capital_Management
gptkb:Drive_Capital
gptkb:JDRF_T1D_Fund
gptkb:Surveyor_Capital
gptkb:Sands_Capital
Octagon Capital
|
|
gptkbp:notableProduct
|
FBX-101
|
|
gptkbp:numberOfEmployees
|
200+
|
|
gptkbp:specializesIn
|
contract development and manufacturing organization (CDMO)
AAV gene therapy manufacturing
|
|
gptkbp:website
|
https://www.forgebiologics.com/
|
|
gptkbp:bfsParent
|
gptkb:Drive_Capital
|
|
gptkbp:bfsLayer
|
6
|